|
⚲
|
| Keyboard |
| Ally Bridge Group NY LLC
✚
|
|
|---|---|
| CRD # | 291072 |
| SEC # | 801-121984 |
| CIK # | 0001822947 |
| AUM | 218.9 M (2026-03-31) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Phone | 646-829-9373 |
| Address | 430 Park Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Praxis Precision Medicines Inc | 10.6 | ||
| Minerva Neurosciences Inc | 10.0 | ||
| OVID Therapeutics Inc | 6.3 | ||
| Compass Pathways PLC | 5.8 | ||
| Tarsus Pharmaceuticals Inc | 5.7 | ||
| Solid Biosciences Inc | 5.5 | ||
| Olivia Ventures Inc | 5.3 | ||
| Promis Neurosciences Inc | 5.3 | ||
| Edgewise Therapeutics Inc | 5.1 | ||
| Uniqure NV | 4.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Ally Bridge Medalpha International Fund Limited | [2021-06-30] | 5.0 M | 118.2 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ally Bridge Medalpha US Fund LP | [2021-06-30] | 14.0 M | 3.5 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Ally Bridge Medalpha Master Fund LP | [2019-03-28] | 5.0 M | 218.9 M |
| Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 218.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 218.9 |
| By Discretionary | ||
| Discretionary | 3 | 218.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 218.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 211.7 | |
| United States Persons | 7.2 | |
| Total | 3 | 218.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Martin Laufer | Director | 69 | 13 | |
| Christopher Lebeau | Director | 34 | 13 | |
| Jarard Blake | Director | 16 | 7 | |
| Fan Yu | Director | 27 | 4 | |
| Vimbai Gurure | Director | 4 | 4 | |
| Anna Yaeger | Director | 3 | 3 | |
| Robert Castrignano | Director | 4 | 2 | |
| Simos Simeonidis | Director | 3 | 2 | |
| Jian Xiao | Director | 2 | 2 | |
| Ally Bridge Group HK Limited | Executive Officer | 2 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001822947] | |
| 3 | [0001822947] | |
| 4 | [0001822947] | |
| SC 13G | [0001822947] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Ally Bridge Group NY LLC | Cogent Biosciences Inc | [2020-11-19] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.5B |
| Clients | 3 (67 non-US) |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300OLTAFEOY6ZKY22 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Amorfix Life Sciences Ltd PMN
Common Shares
|
2026-02-03 | Buy | 700,741 | $12.13 | 8,499,988 |
|
Amorfix Life Sciences Ltd PMN
Warrants · derivative
|
2026-02-03 | Buy | 700,741 | ||
|
Amorfix Life Sciences Ltd PMN
Option (right to buy) · derivative
|
2025-10-22 | Grant | 40,000 | $0.00 | |
|
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
|
2023-06-16 | Other | 965,130 | ||
|
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
|
2023-06-16 | Other | 6,818,181 | ||
|
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
|
2023-03-13 | Buy | 6,818,181 | $0.32 | 2,181,818 |
|
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
|
2023-03-13 | Buy | 965,130 | $0.32 | 308,842 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2022-04-04 | Buy | 2,974,117 | $1.06 | 3,152,564 |
|
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
|
2022-04-04 | Buy | 5,571,764 | $1.06 | 5,906,070 |
|
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
|
2022-04-04 | Buy | 1,487,058 | $1.06 | 1,576,281 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2022-04-04 | Buy | 11,143,529 | $1.06 | 11,812,141 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-31 | Buy | 6,943 | $15.00 | 104,145 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-31 | Buy | 5,727 | $15.00 | 85,905 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-29 | Buy | 45 | $14.00 | 630 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-29 | Buy | 55 | $14.00 | 770 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-28 | Buy | 3,894 | $13.98 | 54,438 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-28 | Buy | 3,213 | $13.98 | 44,918 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-24 | Buy | 4,019 | $13.99 | 56,226 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-24 | Buy | 4,871 | $13.99 | 68,145 |
|
MYOS RENS Technology Inc MDVL
Common Stock
|
2020-12-23 | Buy | 9,810 | $13.99 | 137,242 |
| showing 20 of 39 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Octagon Asset Management LLC
✚
|
NC | 221.2 M |
|
Triavera Capital LLC
✚
|
CA | 220.6 M |
|
Incision Capital Management LP
✚
|
CA | 220.3 M |
|
Sunstone Asset Management LP
✚
|
NY | 220.2 M |
|
Tolis Advisors LP
✚
|
NY | 219.6 M |
|
Ripple Effect Asset Management LP
✚
|
NY | 218.4 M |
|
Butler Hall Capital LLC
✚
|
CA | 218.3 M |
|
Jackson Hill Advisors LLC
✚
|
TX | 217.9 M |
|
Oppvest LLC
✚
|
NY | 217.8 M |
|
Mara River Capital Management LP
✚
|
FL | 217.7 M |